Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells

Journal of Hepatology

Volumn 50, Issue 6, 2009, Pages 1102-1111

  Trappoliere, Marco ^a   Caligiuri, Alessandra ^a   Schmid, Monika ^a   Bertolani, Cristiana ^a   Failli, Paola ^a   Vizzutti, Francesco ^a   Novo, Erica ^b   Manzano, Carlo di ^c   Marra, Fabio ^a   Loguercio, Carmela ^c   Pinzani, Massimo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Fibrogenesis; Hepatic inflammation; Silybin

Indexed keywords

I KAPPA B ALPHA; INTERLEUKIN 1; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RAF PROTEIN; SILIBININ; SODIUM PROTON EXCHANGE PROTEIN 1;

ANTIFIBROGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ACTIVATION; CELL ISOLATION; CELL MOTILITY; CELL PROLIFERATION; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STELLATE CELL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CALCIUM; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; COLLAGEN TYPE I; DNA; HEPATIC STELLATE CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; I-KAPPA B PROTEINS; INTERLEUKIN-1BETA; INTERLEUKIN-8; LIVER CIRRHOSIS; MATRIX METALLOPROTEINASE 2; MODELS, BIOLOGICAL; PLATELET-DERIVED GROWTH FACTOR; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SILYMARIN;

EID: 67349165577     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.02.023     Document Type: Article

References (41)

1. Parola M., Marra F., and Pinzani M. Myofibroblast-like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol Aspects Med 29 (2008) 58-66
2. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88 (2008) 125-172
3. Guimarães E.L., Franceschi M.F., Grivicich I., Dal-Pizzol F., Moreira J.C., Guaragna R.M., et al. Relationship between oxidative stress levels and activation state on a hepatic stellate cell line. Liver Int 26 (2006) 477-485
4. Di Sario A., Svegliati Baroni G., Bendia E., Ridolfi F., Saccomanno S., Ugili L., et al. Intracellular pH regulation and Na+/H+ exchange activity in human hepatic stellate cells: effect of platelet-derived growth factor, insulin-like growth factor 1 and insulin. J Hepatol 34 (2001) 378-385
5. Aleffi S., Petrai I., Bertolani C., Parola M., Colombatto S., Novo E., et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42 (2005) 1339-1348
6. Tsuruta S., Nakamuta M., Enjoji M., Kotoh K., Hiasa K., Egashira K., et al. Anti-monocyte chemoattractant protein-1 gene therapy prevents dimethylnitrosamine-induced hepatic fibrosis in rats. Int J Mol Med 14 (2004) 837-842
7. Wen Z., Dumas T.E., Schrieber S.J., Hawke R.L., Fried M.W., and Smith P.C. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 36 (2008) 65-72
8. Gazák R., Walterová D., and Kren V. Silybin and silymarin, new and emerging applications in medicine. Curr Med Chem 14 (2007) 315-338
9. Schümann J., Prockl J., Kiemer A.K., Vollmar A.M., Bang R., and Tiegs G. Silibinin protects mice from T cell-dependent liver injury. J Hepatol 39 (2003) 333-340
10. Singh R.P., Gu M., and Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 68 (2008) 2043-2050
11. Raina K., Blouin M.J., Singh R.P., Majeed N., Deep G., Varghese L., et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 67 (2007) 11083-11091
12. Roy S., Kaur M., Agarwal C., Tecklenburg M., Sclafani R.A., and Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 6 (2007) 2696-2707
13. Katiyar S.K., Roy A.M., and Baliga M.S. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol Cancer Ther 4 (2005) 207-216
14. Polyak S.J., Morishima C., Shuhart M.C., Wang C.C., Liu Y., and Lee D.Y. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 132 (2007) 1925-1936
15. Ferenci P., TM S., Kerschner H., Rutter K., Beinhardt S., Hofer H., et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135 (2008) 1561-1567
16. Jia J.D., Bauer M., Cho J.J., Ruehl M., Milani S., Boigk G., et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 35 (2001) 392-398
17. Di Sario A., Bendia E., Taffetani S., Omenetti A., Candelaresi C., Marzioni M., et al. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. Dig Liver Dis 37 (2005) 869-876
18. Boigk G., Stroedter L., Herbst H., Waldschmidt J., Riecken E.O., and Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26 (1997) 643-649
19. Fuchs E.C., Weyhenmeyer R., and Weiner O.H. Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. Arzneimittelforschung 47 (1997) 1383-1387
20. Casini A., Pinzani M., Milani S., Grappone C., Galli G., Jezequel A.M., et al. Regulation of extracellular matrix synthesis by transforming growth factor-beta1 in human fat-storing cells. Gastroenterology 105 (1993) 245-253
21. Pinzani M., Failli P., Ruocco C., Casini A., Milani S., Baldi E., et al. Fat-storing cells as liver-specific pericytes: spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 90 (1992) 642-646
22. Pinzani M., Gesualdo L., Sabbah G.M., and Abboud H.E. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured liver fat-storing cells. J Clin Invest 84 (1989) 1786-1793
23. Marra F., Gentilini A., Pinzani M., Ghosh Choudhury G., Parola M., Herbst H., et al. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's action on hepatic stellate cells. Gastroenterology 112 (1997) 1297-1306
24. Rezvani H.R., Dedieu S., North S., Belloc F., Rossignol R., Letellier T., et al. Hypoxia inducible factor-1alpha, a key factor in the keratinocyte response to UVB exposure. J Biol Chem 282 (2007) 16413-16422
25. Failli P., Ruocco C., De Franco R., Caligiuri A., Gentilini A., Giotti A., et al. The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influx. Am J Physiol 269 (1995) 1133-1139
26. Haukeland J.W., Damås J.K., Konopski Z., Loberg E.M., Haaland T., Goverud I., et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44 (2006) 1167-1174
27. Westerbacka J., Cornér A., Kolak M., Makkonen J., Turpeinen U., Hamsten A., et al. Insulin regulation of MCP-1 in human adipose tissue of obese and lean women. Am J Physiol Endocrinol Metab 294 (2008) E841-E845
28. Pinzani M., and Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 21 (2001) 397-416
29. Caligiuri A., De Franco R.M., Romanelli R.G., Gentilini A., Meucci M., Failli P., et al. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology 124 (2003) 504-520
30. Trouillas P., Marsal P., Svobodová A., Vostálová J., Gazák R., Hrbác J., et al. Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study. J Phys Chem A 112 (2008) 1054-1063
31. Kreuzer J., Viedt C., Brandes R.P., Seeger F., Rosenkranz A.S., Sauer H., et al. Platelet-derived growth factor activates production of reactive oxygen species by NAD(P)H oxidase in smooth muscle cells through Gi1,2. FASEB J 17 (2003) 38-40
32. 2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci USA 105 (2008) 7147-7152
33. Casini A., Ceni E., Salzano R., Biondi P., Parola M., Galli A., et al. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology 25 (1997) 361-367
34. Marra F., DeFranco R., Grappone C., Parola M., Milani S., Leonarduzzi G., et al. Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J Investig Med 47 (1999) 66-75
35. Dehmlow C., Murawski N., and de Groot H. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 58 (1996) 1591-1600
36. Dehmlow C., Erhard J., and de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23 (1996) 749-754
37. Singh R.P., Dhanalakshmi S., Agarwal C., and Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24 (2005) 1188-1202
38. Wen Z., Dumas T.E., Schrieber S.J., Hawke R.L., Fried M.W., and Smith P.C. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 36 (2008) 65-72
39. Carini R., Comoglio A., Albano E., and Poli G. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016. Biochem Pharmacol 43 (1992) 2111-2115
40. Comoglio A., Tomasi A., Malandrino S., Poli G., and Albano E. Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Biochem Pharmacol 50 (1995) 1313-1316
41. Zhao J., and Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 20 (1999) 2101-2108